A follow-up trial in lung cancer using canakinumab in combination with radiation or chemotherapy failed to demonstrate efficacy, implying that IL-1β blockade may be beneficial for preventing cancer initiation but does not augment treatment [124]. Here, IL1B is linked to cancer.